The relationship between R&D expenses and pipeline drugs
Which developments and trends can be identified with regard to R&D spending in the pharmaceutical industry since 2015 and how does this relate to the number of drugs in the pipeline? Our research shows: Between 2015 and 2020, the top 15 pharmaceutical companies have seen steady growth in R&D spending, offset by a declining number of drugs in the pipeline. To stay at the top, be innovative and meet increasing regulatory requirements, companies have to continuously optimize their R&D efforts. Looking at the figures in detail, 10 of the 15 largest global pharmaceutical companies have seen the number of pipeline drugs decline. With the constant increase in R&D spending, a clear focus on the efficiency of R&D processes is required.